Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
Ontology highlight
ABSTRACT: RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET imaging, may be effective in detecting residual disease after radiofrequency ablation of liver metastases in patients with colorectal cancer.
PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it works for early detection of residual disease in patients undergoing radiofrequency ablation of liver metastases from colorectal cancer.
DISEASE(S): Neoplasm Metastasis,Colorectal Cancer,Colorectal Neoplasms,Metastatic Cancer
PROVIDER: 2041940 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA